NL-201 (Neoleukin Therapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameNL-201 (Neoleukin Therapeutics)
Drug Alias NameNL-201
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma stimulants
TargetsInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeoleukin Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeurogene Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A